Pharmaceutical & Biotech
News and Insights
Another example of how far technology has come!
GlaxoSmithKline Plc will be conducting a rheumatoid arthritis study using Apple's Inc.'s ResearchKit. The company has created an app that will use the phone's censors to allow them to track motion of the study's participants. GSK hopes to track the mobility of 300 people over a 3 month period. Additionally, they will be asked to input information regarding physical and emotional symptoms. If the trial is a success, it could increase the pharmaceutical industry's desire to use Apple products for future research. Click here to view the entire article. ...
Companies have increased prices on top-selling medications in Q1
Despite the public outcry and congressional discussions from Turing Pharmaceuticals and Valeant's drug price increases last fall, many companies followed suit and have raised prices on their top-selling medications in the first quarter of 2016. Even though there have been many complaints, this has led to increased profits. Price increases in big-selling medications were so common in the first quarter that Wall Street Journal found more than two-thirds of the 20 largest biopharma companies used the move to grow sales. Click here to view the entire article. ...
Biologics exclusivity may be reduced
In 2009, President Obama proposed decreasing the exclusivity of biologic drugs from 12 years to 7 years. In the years since, federal efforts to control drug pricing have failed due to a deadlocked Congress. Biological products often represent the cutting-edge of biomedical research but are often quite pricey. U.S. Rep. Jan Schakowsky, U.S. Sen. Sherrod Brown and Sen. John McCain have joined forces and are introducing the Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act. "Far too many Americans are being unfairly burdened by the skyrocketing costs of prescription drugs," Sen. McCain said. "It's simply unacceptable that patients have to worry about filling a prescription because they can't afford to pay for it." Click here to view the entire article. ...
Outcomes-based pricing is on the rise
Outcomes-based pricing is on the rise in the US. Currently about 14% of US payers have at least on pay-for-performance pricing arrangement, this is up from 10% in 2014. The pluses are that discounts and rebates will rise if a drug is performing well. If a drug not performing well, rebates will decrease. A couple of glitches with the outcomes-based pricing are patients adhering to their prescription plan for usage and the need for expansion of the current electronic data collection system. Click here to view the entire article. ...
Boehringer Ingelheim starting a rewards program for COPD patients
In an effort to help patients adhere to their treatment plan, Boehringer Ingleheim is beginning a new rewards program for those using Spriva Respimat for the treatment of COPD. Patients will earn points for prescription refills, daily medication check-ins and taking quizzes and surveys. These points can then be used to purchase gift cards a companies such as Starbucks and Amazon. If all goes well, Boehringer plans to extend the rewards program to include its 5 other drugs for asthma and COPD. Click here to read the entire article. ...
2016 ASCO Conference
The American Society of Clinical Oncology's (ASCO) annual meeting brings together 30,000 oncology professionals from around the world. This year's meeting is being held in Chicago, IL. The conference begain on June 3rd and ends on June 7th. It is a chance to attend educational sessions, discover new therapies and learn about trends in the industry. To learn a little about what happened at the 2016 conference please click here. ...
Big Pharma Executives are Moving to Small Biotech Start-ups
Here is an interesting article on the reasoning behind why more and more executives from Big Pharma to are moving on to lead small start-up Biotechs. The small companies offer the classic high-risk, high-reward contrast and the freedom from bureaucracy or politics. Additionally, in recent years more drugs that received approval were created at these small start-ups. Click here to view the entire article. ...
How to look good for your Skype interview
Please take a minute to view this 4 minute video with tips and guidance on how to look your best for an upcoming Skype interview. The four basic steps include: sound, location, good lighting and dressing appropriately. ...
Amgen – ‘Breakaway from Cancer’ Campaign
Patrick Dempsey, who played a doctor on "Grey's Anatomy" is starring in a new campaign for Amgen to help fight cancer. The campaign supports efforts for the prevention of cancer, support for those battling the disease, provides financial assistance and aids survivors. Dempsey's mother died from ovarian cancer in 2014. He founded the Patrick Dempsey Center for Cancer Hope & Healing in 2008. Click here to view the entire article ...
Changes coming to Novartis
In an effort to show the importance of oncology to Novartis, it will be splitting the company into two business units. One will be focused on cancer and the second on other drugs. Additionally, David Epstein, who has been with Novartis since 1989, will be departing the company later this year to pursue new opportunities in the US. He will be replaced by two people. Paul Hudson is coming over from AstraZeneca to lead the pharmaceutical business unit and Bruno Strigini, who currently head of Novartis Oncology, will take over as lead the newly created oncology business. Click here to view the entire article. ...
1 of 3